Primary Job Title Chairman Primary Organization Link Immunotherapeutics
Location Sammamish, Washington, United States Regions Greater Seattle Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Roger Ulrich, Ph.D., is the Chairman at Link Immunotherapeutics and a Senior Advisor on the Frazier Healthcare Partners Life Sciences team, and brings several decades of both leadership and operational experience within the pharmaceutical industry. He was Chief Scientific Officer and a member of the founding Board of Directors of Acerta Pharma
through its majority-share acquisition by AstraZeneca. He was previously Co-founder and Chief Development Officer with Calistoga Pharmaceuticals. Calistoga was acquired by Gilead Sciences, and he continued with Gilead to help with the Calistoga integration and complete the development of its lead product candidate. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories, where he helped guide the Merck integration of Seattle-based Rosetta Inpharmatics. He was also Director of Drug Safety Evaluation at Abbott Laboratories, and was Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his career in the pharmaceutical industry, he held research positions at West Virginia and Michigan State Universities, and at Argonne National Laboratories. He currently serves on the Boards of Acerta Pharma, Remedy Pharmaceuticals, and Aminex, and serves as a scientific advisor to several small companies. Dr. Ulrich received his Ph.D. in cellular and molecular biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He holds several patents, has authored more than 120 publications and is a Fellow of the Academy of Toxicological Sciences.
